Cargando…

Pemetrexed versus Gefitinib versus Erlotinib in Previously Treated Patients with Non-Small Cell Lung Cancer

BACKGROUND/AIMS: The efficacy and safety of pemetrexed, gefitinib, and erlotinib administration in previously treated patients with non-small cell lung cancer (NSCLC) were compared. METHODS: The study patients met the following criteria: histologically confirmed, previously treated advanced (stage I...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hong, Junshik, Kyung, Sun Young, Lee, Sang Pyo, Park, Jeong Woong, Jung, Sung Hwan, Lee, Jae-Ik, Park, Se Hoon, Sym, Sun Jin, Park, Jinny, Cho, Eun Kyung, Shin, Dong Bok, Lee, Jae Hoon
Formato:	Texto
Lenguaje:	English
Publicado:	The Korean Association of Internal Medicine 2010
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2932943/ https://www.ncbi.nlm.nih.gov/pubmed/20830227 http://dx.doi.org/10.3904/kjim.2010.25.3.294

Ejemplares similares

Randomized Phase II Study of Pemetrexed Versus Gefitinib in Previously Treated Patients with Advanced Non-small Cell Lung Cancer
por: Kim, Young Saing, et al.
Publicado: (2016)

Additional rituximab-CHOP (R-CHOP) versus involved-field radiotherapy after a brief course of R-CHOP in limited, non-bulky diffuse large B-cell lymphoma: a retrospective analysis
por: Hong, Junshik, et al.
Publicado: (2010)

Epidermal Growth Factor Receptor Mutations and the Clinical Outcome in Male Smokers with Squamous Cell Carcinoma of Lung
por: Park, Se Hoon, et al.
Publicado: (2009)

Anemia as a useful biomarker in patients with diffuse large B-cell lymphoma treated with R-CHOP immunochemotherapy
por: Hong, Junshik, et al.
Publicado: (2014)

Efficacy and Safety of Afatinib for EGFR-mutant Non-small Cell Lung Cancer, Compared with Gefitinib or Erlotinib
por: Kim, Youjin, et al.
Publicado: (2019)

Prognostic Factors for Risk Stratification of Patients with Recurrent or Metastatic Pancreatic Adenocarcinoma Who Were Treated with Gemcitabine-Based Chemotherapy
por: Park, Inkeun, et al.
Publicado: (2016)

Epidermal growth factor receptor mutation and pattern of brain metastasis in patients with non-small cell lung cancer
por: Baek, Min Young, et al.
Publicado: (2018)

The Role of Brain Radiotherapy before First-Line Afatinib Therapy, Compared to Gefitinib or Erlotinib, in Patients with EGFR-Mutant Non–Small Cell Lung Cancer
por: Jung, Hyun Ae, et al.
Publicado: (2023)

Baseline renal function as a prognostic indicator in patients with newly diagnosed diffuse large B-cell lymphoma
por: Hong, Junshik, et al.
Publicado: (2016)

Docetaxel plus cisplatin is effective for patients with metastatic breast cancer resistant to previous anthracycline treatment: a phase II clinical trial
por: Park, Se Hoon, et al.
Publicado: (2005)

A Randomized, Open-Label, Phase II Study Comparing Pemetrexed Plus Cisplatin Followed by Maintenance Pemetrexed versus Pemetrexed Alone in Patients with Epidermal Growth Factor Receptor (EGFR)-Mutant Non-small Cell Lung Cancer after Failure of First-Line EGFR Tyrosine Kinase Inhibitor: KCSG-LU12-13
por: Yoo, Kwai Han, et al.
Publicado: (2019)

The different central nervous system efficacy among gefitinib, erlotinib and afatinib in patients with epidermal growth factor receptor mutation-positive non-small cell lung cancer
por: Jung, Hyun Ae, et al.
Publicado: (2020)

Gefitinib or erlotinib in previously treated non–small‐cell lung cancer patients: a cohort study in Taiwan
por: Chang, Chia‐Hao, et al.
Publicado: (2017)

Erlotinib plus gemcitabine versus gemcitabine for pancreatic cancer: real-world analysis of Korean national database
por: Shin, Sangjin, et al.
Publicado: (2016)

Efficacy and dose of afatinib in patients with non‐small cell lung cancer after failure of prior gefitinib or erlotinib treatment
por: Choi, Hayoung, et al.
Publicado: (2021)

Predicting Tumor Responses to Gefitinib and Erlotinib
Publicado: (2005)

Clinical efficacy of erlotinib, a salvage treatment for non-small cell lung cancer patients following gefitinib failure
por: Cho, Kyoung Min, et al.
Publicado: (2015)

Screening PCR Versus Sanger Sequencing: Detection of CALR Mutations in Patients With Thrombocytosis
por: Jeong, Ji Hun, et al.
Publicado: (2016)

Pemetrexed Continuation Maintenance versus Conventional Platinum-Based Doublet Chemotherapy in EGFR-Negative Lung Adenocarcinoma: Retrospective Analysis
por: Paik, Seung Sook, et al.
Publicado: (2018)

Pemetrexed in Previously Treated Non-small Cell Lung Cancer Patients with Poor Performance Status
por: Sun, Young JUNG, et al.
Publicado: (2011)

Correction: Predicting Tumor Responses to Gefitinib and Erlotinib
Publicado: (2012)

Oxaliplatin-Induced Immune-Mediated Thrombocytopenia: A Case Report
por: Woo, Hyun Sun, et al.
Publicado: (2015)

Predictive factors for a long-term response duration in non-squamous cell lung cancer patients treated with pemetrexed
por: Park, Sojung, et al.
Publicado: (2016)

Successful erlotinib rechallenge after both gefitinib- and erlotinib-induced interstitial lung diseases
por: Arakawa, Nobuhito, et al.
Publicado: (2013)

Exonuclease 1 genetic variant is associated with clinical outcomes of pemetrexed chemotherapy in lung adenocarcinoma
por: Hong, Mi Jeong, et al.
Publicado: (2022)

Tolerability and Outcomes of First-Line Pemetrexed-Cisplatin Followed by Gefitinib Maintenance Therapy Versus Gefitinib Monotherapy in Korean Patients with Advanced Nonsquamous Non-small Cell Lung Cancer: A Post Hoc Descriptive Subgroup Analysis of a Randomized, Phase 3 Trial
por: Kang, Jin Hyoung, et al.
Publicado: (2016)

Genetic Variants in Histone Modification Regions Predict Clinical Outcomes of Pemetrexed Chemotherapy in Lung Adenocarcinoma
por: Lee, Yong Hoon, et al.
Publicado: (2023)

Lorlatinib Versus Pemetrexed-Based Chemotherapy in Patients With ALK-rearranged NSCLC Previously Treated With Alectinib
por: Takeyasu, Yuki, et al.
Publicado: (2022)

Erlotinib intercalating pemetrexed/cisplatin versus erlotinib alone in Chinese patients with brain metastases from lung adenocarcinoma: a prospective, non-randomised, concurrent controlled trial (NCT01578668)
por: Yang, Haihong, et al.
Publicado: (2017)

Two Lung Masses with Different Responses to Pemetrexed
por: Park, Kwang Young, et al.
Publicado: (2010)

Gefitinib-Induced Interstitial Lung Disease in Korean Lung Cancer Patients
por: Beom, Seung-Hoon, et al.
Publicado: (2016)

N-ras Mutation Detection by Pyrosequencing in Adult Patients with Acute Myeloid Leukemia at a Single Institution
por: Jeong, Ji Hun, et al.
Publicado: (2013)

KRAS Mutations and Primary Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib
por: Pao, William, et al.
Publicado: (2005)

Efficacy of gefitinib or erlotinib in patients with squamous cell lung cancer
por: Song, Zhengbo, et al.
Publicado: (2013)

Case of Proteinuria, Worsening Hypertension, and Glomerular Endotheliosis With Erlotinib and Gefitinib
por: Latcha, Sheron, et al.
Publicado: (2018)

Sequentially administrated of pemetrexed with icotinib/erlotinib in lung adenocarcinoma cell lines in vitro
por: Feng, Xiuli, et al.
Publicado: (2017)

Cervical Lymphadenopathy Mimicking Angioimmunoblastic T-Cell Lymphoma after Dapsone-Induced Hypersensitivity Syndrome
por: Rim, Min Young, et al.
Publicado: (2012)

Pemetrexed-Erlotinib, Pemetrexed Alone, or Erlotinib Alone as Second-Line Treatment for East Asian and Non-East Asian Never-Smokers with Locally Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer: Exploratory Subgroup Analysis of a Phase II Trial
por: Lee, Dae Ho, et al.
Publicado: (2015)

Activity of pemetrexed and high-dose gefitinib in an EGFR-mutated lung adenocarcinoma with brain and leptomeningeal metastasis after response to gefitinib
por: Yuan, Ying, et al.
Publicado: (2012)

Pemetrexed Singlet Versus Nonpemetrexed-Based Platinum Doublet as Second-Line Chemotherapy after First-Line Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor Failure in Non-small Cell Lung Cancer Patients with EGFR Mutations
por: Park, Sehhoon, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_to41sm4iprc27ba65fi2fpjcui